Assenagon Asset Management S.A. Sells 112,384 Shares of Axon Enterprise, Inc $AXON

Assenagon Asset Management S.A. cut its position in Axon Enterprise, Inc (NASDAQ:AXON) by 54.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 95,045 shares of the biotechnology company’s stock after selling 112,384 shares during the period. Assenagon Asset Management S.A.’s holdings in Axon Enterprise were worth $40,365,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Krilogy Financial LLC raised its holdings in shares of Axon Enterprise by 120.3% in the 1st quarter. Krilogy Financial LLC now owns 1,344 shares of the biotechnology company’s stock worth $528,000 after acquiring an additional 734 shares during the last quarter. Paragon Capital Management Inc. boosted its position in shares of Axon Enterprise by 61.6% during the first quarter. Paragon Capital Management Inc. now owns 1,841 shares of the biotechnology company’s stock valued at $782,000 after buying an additional 702 shares during the last quarter. SG Americas Securities LLC grew its holdings in Axon Enterprise by 56.2% during the first quarter. SG Americas Securities LLC now owns 26,112 shares of the biotechnology company’s stock worth $11,090,000 after buying an additional 9,398 shares in the last quarter. Diversified Trust Co grew its holdings in Axon Enterprise by 20.8% during the first quarter. Diversified Trust Co now owns 11,906 shares of the biotechnology company’s stock worth $5,056,000 after buying an additional 2,054 shares in the last quarter. Finally, WESPAC Advisors SoCal LLC raised its position in Axon Enterprise by 37.1% in the 1st quarter. WESPAC Advisors SoCal LLC now owns 5,144 shares of the biotechnology company’s stock valued at $2,185,000 after buying an additional 1,393 shares during the last quarter. Institutional investors own 79.08% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on AXON shares. Barclays dropped their price objective on Axon Enterprise from $682.00 to $523.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. The Goldman Sachs Group set a $535.00 target price on shares of Axon Enterprise in a report on Thursday, May 7th. Weiss Ratings raised shares of Axon Enterprise from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, May 8th. Piper Sandler restated an “overweight” rating and set a $674.00 price target on shares of Axon Enterprise in a report on Monday, June 15th. Finally, Zacks Research raised shares of Axon Enterprise from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 19th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Axon Enterprise has a consensus rating of “Moderate Buy” and a consensus price target of $712.75.

Axon Enterprise Trading Down 2.6%

NASDAQ:AXON opened at $444.73 on Friday. The company has a current ratio of 2.27, a quick ratio of 1.93 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $35.85 billion, a PE ratio of 178.61, a price-to-earnings-growth ratio of 8.30 and a beta of 1.45. The firm’s 50 day moving average is $419.39 and its 200 day moving average is $482.20. Axon Enterprise, Inc has a 12 month low of $339.01 and a 12 month high of $885.91.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.01. Axon Enterprise had a return on equity of 3.78% and a net margin of 6.90%.The business had revenue of $807.35 million during the quarter, compared to analyst estimates of $778.90 million. During the same period in the prior year, the company earned $1.47 earnings per share. Axon Enterprise’s revenue was up 33.7% compared to the same quarter last year. Sell-side analysts expect that Axon Enterprise, Inc will post 1.82 earnings per share for the current year.

Key Axon Enterprise News

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Citizens JMP reaffirmed its Market Outperform rating on Axon and kept a $700 price target, implying meaningful upside from current levels as adoption of AI, 911 dispatch tools, and drone technology accelerates across U.S. agencies. Benzinga article
• Positive Sentiment: Coverage around Dedrone highlighted expanding counter-drone capabilities, with the business reportedly generating more bookings than its acquisition price, reinforcing the view that Axon’s platform expansion is creating real revenue momentum. Axon stock trades up article
• Positive Sentiment: Multiple articles framed Axon as a beneficiary of rising demand for AI-powered public safety tools, including body cameras, software, dispatch, and drone-related products, which supports the long-term growth narrative for AXON. TipRanks article
• Neutral Sentiment: Axon was also noted as a trending stock on Zacks and in broader industry outlook pieces, which reflects heightened investor attention but does not by itself change fundamentals. Zacks trending stock article
• Neutral Sentiment: A report on short interest showed effectively no active short positioning, so it does not appear to be a meaningful driver of the stock right now.

Insider Activity

In other news, CEO Patrick W. Smith sold 20,000 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $500.00, for a total transaction of $10,000,000.00. Following the completion of the transaction, the chief executive officer owned 3,060,997 shares in the company, valued at approximately $1,530,498,500. This represents a 0.65% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CRO Cameron Brooks sold 1,242 shares of Axon Enterprise stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $500.00, for a total value of $621,000.00. Following the completion of the sale, the executive directly owned 49,710 shares of the company’s stock, valued at approximately $24,855,000. This trade represents a 2.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 38,989 shares of company stock worth $19,090,083. 4.20% of the stock is owned by company insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.